Maas Biolab is a private neuropharmaceutical company developing a treatment for amyotrophic lateral sclerosis – using cyclosporin as a neuro-protectant drug. Maas Biolab's patent and related intellectual property rights consist formulation patents and production patents for cyclosporins as neuroprotective agents. Maas Biolab has FDA Orphan Drug Designation for cyclosporin to treat ALS.